The DOI matches its Crossref record.
A Double-Blind, Placebo-Controlled Study of Citalopram With and Without Lithium in the Treatment of Therapy-Resistant Depressive Patients: A Clinical, Pharmacokinetic, and Pharmacogenetic Investigation
Abstract
Sixty-nine depressive patients (DSM III criteria: 296.2, 296.3, 296.5, 300.4) were treated with 40 to 60 mg citalopram (CIT) daily for 4 weeks. Among them, 45 responded to treatment (improvement > 50% on the 21-item Hamilton Rating Scale for Depression [HAM-D]) and continued their treatment for another week before being released from the study. The 24 nonresponders were randomized and comedicated under double-blind conditions with lithium carbonate (Li) (2 x 400 mg/day) (CIT-Li group) or with placebo (CIT-Pl group) from days 29 to 35. For days 36 to 42, the patients of both subgroups were treated openly with Li (800 mg/day) in addition to the ongoing CIT treatment. On day 35, 6 of 10 patients responded to the CIT-Li combination, whereas 2 of 14 patients only responded to the CIT-Pl combination. This group difference reached significance (p < 0.05) on day 35 with lower HAM-D total scores in the CIT-Li group. No evidence was seen of a pharmacokinetic interaction between CIT and Li, and this combination was well tolerated. Patients were phenotyped with dextromethorphan and mephenytoin at baseline and at day 28. As evaluated at baseline, three patients (responders) were poor metabolizers of dextromethorphan and six patients (three responders and three nonresponders) of mephenytoin. On day 28, the ratio CIT/N-desmethylCIT (DCIT) in plasma was significantly higher in poor than in extensive metabolizers of mephenytoin (p = 0.0001), and there was a significant positive correlation between the metabolic ratio of dextromethorphan and the ratio DCIT/N-didesmethylCIT in plasma (p < 0.001). These findings illustrate the role of CYP2D6 and CYP2C19 in the metabolism of CIT. It can be concluded that Li addition to CIT is effective in patients not responding to CIT alone without any evidence of an accentuation or provocation of adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 39
- de Montigny, 1981, Br J Psychiatry, 138, 252, 10.1192/bjp.138.3.252 · DOI · Paper page
- Schopf, 1989, Pharmacopsychiatry, 22, 174, 10.1055/s-2007-1014602 · doi:10.1055/s-2007-1014602
- Austin, 1991, Br J Psychiatry, 159, 510, 10.1192/bjp.159.4.510 · DOI
- Delgado, 1988, J Affect Disord, 15, 55, 10.1016/0165-0327(88)90009-2 · DOI
- Ontiveros, 1991, Acta Psychiatr Scand, 83, 188, 10.1111/j.1600-0447.1991.tb05522.x · DOI
- Kuroda, 1994, Eur J Pharmacol (Molecular Pharmacology Section), 268, R3, 10.1016/0922-4106(94)90127-9 · DOI
- Fava, 1994, Am J Psychiatry, 151, 1372, 10.1176/ajp.151.9.1372 · DOI · Paper page
- Katona, 1995, Br J Psychiatry, 166, 80, 10.1192/bjp.166.1.80 · DOI · Paper page
- Hawley, 1994, J Psychopharmacol, 8, 266, 10.1177/026988119400800412 · DOI
- Dinah, 1993, Acta Psychiatr Scand, 88, 300, 10.1111/j.1600-0447.1993.tb03461.x · doi:10.1111/j.1600-0447.1993.tb03461.x
- Cowen, 1991, Br J Psychiatry, 159, 341, 10.1192/bjp.159.3.341 · DOI
- McCance-Katz, 1992, Psychopharmacology, 108, 93, 10.1007/BF02245291 · DOI
- Nixon, 1994, Psychopharmacology, 115, 59, 10.1007/BF02244752 · DOI
- Hyttel, 1982, Prog Neuropsychopharmacol Biol Psychiatry, 6, 277, 10.1016/S0278-5846(82)80179-6 · DOI · Paper page
- Milne, 1991, Drugs, 41, 450, 10.2165/00003495-199141030-00008 · DOI · Paper page
- Luo, 1993, Int Clin Psychopharmacol, 8, 3, 10.1097/00004850-199300810-00001 · DOI
- Uehlinger, 1995, Int J Geriatr Psychiatry, 10, 281, 10.1002/gps.930100404 · DOI
- Oyehaug, 1984, J Chromatogr Biomed Appl, 308, 199, 10.1016/0378-4347(84)80209-1 · DOI
- Sindrop, 1993, Ther Drug Monit, 15, 11, 10.1097/00007691-199302000-00002 · DOI · Paper page
- Daly, 1993, Pharmacol Ther, 57, 129, 10.1016/0163-7258(93)90053-G · DOI · Paper page
- Spina, 1994, Pharmacol Res, 29, 121, 10.1016/1043-6618(94)80036-7 · doi:10.1016/1043-6618(94)80036-7
- Gorski, 1994, Biochem Pharmacol, 48, 173, 10.1016/0006-2952(94)90237-2 · DOI
- Souche, 1991, Encephale, XVII, 213
- Hamilton, 1967, Br J Soc Clin Psychol, 6, 278, 10.1111/j.2044-8260.1967.tb00530.x · DOI · Paper page
- Noveske, 1989, Am J Psychiatry, 146, 1515
- Schopf, 1989, Pharmacopsychiatry, 22, 183, 10.1055/s-2007-1014603 · DOI
- Lingjaerde, 1987, Acta Psychiatr Scand, 334, 81
- Reymond, 1993, J Chromatogr Biomed Appl, 616, 221, 10.1016/0378-4347(93)80389-L · DOI
- Baumann, 1992, Ther Drug Monit, 14, 1, 10.1097/00007691-199202000-00001 · doi:10.1097/00007691-199202000-00001
- Zhang, 1991, Br J Clin Pharmacol, 31, 350, 10.1111/j.1365-2125.1991.tb05542.x · doi:10.1111/j.1365-2125.1991.tb05542.x
- Pope, 1988, Am J Psychiatry, 145, 1292, 10.1176/ajp.145.10.1292 · doi:10.1176/ajp.145.10.1292
- Ohman, 1993, Pharmacopsychiatry, 26, 263, 10.1055/s-2007-1014367 · doi:10.1055/s-2007-1014367
- Salama, 1989, Am J Psychiatry, 146, 278
- Steinbach, 1991, Am J Psychiatry, 148, 705, 10.1176/ajp.148.6.705 · DOI · Paper page
- Brady, 1991, J Clin Psychiatry, 52, 509
- Baumann, 1995, Rev Contemp Pharmacother, 6, 287
- Gram, 1993, Ther Drug Monit, 15, 18, 10.1097/00007691-199302000-00003 · DOI
- Brosen, 1993, Clin Investig, 71, 1002, 10.1007/BF00180032 · doi:10.1007/bf00180032
- Coutts, 1994, J Pharmacol Toxicol Methods, 31, 177, 10.1016/1056-8719(94)90001-9 · DOI
Cited by
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Fava, M., Rush, A. J., Trivedi, M. H., Nierenberg, A. A., Thase, M. E., Sackeim, H. A., Quitkin, F. M., Wisniewski, S., Lavori, P. W., Rosenbaum, J. F., et al. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(02)00107-7 · Cited by 519
Connolly, K. R., & Thase, M. E. (2011) · Drugs · doi:10.2165/11587620-000000000-00000 · Cited by 462
Management of Treatment-Resistant Depression: Challenges and Strategies
Voineskos, D., Daskalakis, Z. J., & Blumberger, D. M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s198774 · Cited by 446
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Metadata
- Authors
- Baumann, P., Nil, R., Souche, A., Montaldi, S., Baettig, D., Lambert, S., Uehlinger, C., Kasas, A., Amey, M., & Jonzier-Perey, M.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1996-08
- Volume
- 16
- Issue
- 4
- Pages
- 307-314
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2083597120
- Cited by
- 173
- References
- 0
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Double-Blind, Placebo-Controlled Study of Citalopram With and Without Lithium in the Treatment of Therapy-Resistant Depressive Patients: A Clinical, Pharmacokinetic, and Pharmacogenetic Investigation. https://app.cochat.ai/papers/10.1097/00004714-199608000-00006
- The paper
- Baumann, P., Nil, R., Souche, A., Montaldi, S., Baettig, D., Lambert, S., Uehlinger, C., Kasas, A., Amey, M., & Jonzier-Perey, M. (1996). A Double-Blind, Placebo-Controlled Study of Citalopram With and Without Lithium in the Treatment of Therapy-Resistant Depressive Patients: A Clinical, Pharmacokinetic, and Pharmacogenetic Investigation. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199608000-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.